Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Abivax SA - American Depositary Shares (NQ:ABVX)

92.58 -0.30 (-0.32%)
Delayed Quote Updated: 1:50 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology. 
Via The Motley Fool
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest ↗
Via Stocktwits
News headline image
Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year ↗
Is there any upside left for this rising biotech? 
Via The Motley Fool
News headline image
2 Reasons Abivax Stock Could 10X by 2036 ↗
Could it be a biotech giant in the making? 
Via The Motley Fool
News headline image
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
From Abivax
Via GlobeNewswire
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Could these two companies be biotech giants in the making? 
Via The Motley Fool
News headline image
Better Long-Term Buy: This Emerging Player or the Industry Leader? ↗
The choice between the two might come down to each investor's goals and risk tolerance. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Prediction: This Healthcare Stock Could Soar by 72% in 2026 ↗
And the share price appreciation could happen pretty soon. 
Via The Motley Fool
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Abivax Provides 2026 Corporate Outlook
From Abivax
Via GlobeNewswire
News headline image
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Could This Potential Move Boost Eli Lilly's Prospects? ↗
The stock already looks unstoppable, and this move won't hurt its momentum. 
Via The Motley Fool
News headline image
The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot
As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year ↗
A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗
Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session. 
Via Stocktwits
Topics ETFs Stocks
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results... 
Via MarketMinute
Topics Intellectual Property
News headline image
Why Abivax Stock Was on Fire Today ↗
Investors were excited about the possibility of a buyout with a high price tag. 
Via The Motley Fool
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Abivax to be Added to Nasdaq Biotechnology Index
From Abivax
Via GlobeNewswire
News headline image
The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains
The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
From Abivax
Via GlobeNewswire
News headline image
Abivax Presents Third Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
2 Under-the-Radar Stocks That Have Soared This Year ↗
These companies are worth your attention. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.